GlaxoSmithKline invests in Africa
GlaxoSmithKline has announced a series of new investments in sub-Saharan Africa designed to address pressing health needs and contribute to long-term business growth. GSK CEO Sir Andrew Wittyhasset out the company’s intent to partner with governments of African countries to help stimulate more research into chronic diseases, increase capacity by localizing medicines supply and strengthen healthcare infrastructure.
This will see GSK make targeted investments of up to $216.3 million in Africa over the next five years, creating at least 500 jobs and contributing to the development of home-grown capabilities and skills in Africa. This builds on GSK’s existing business base in sub-Saharan Africa, which currently employs around 1,500 people in over 40 countries, including at three existing local manufacturing sites in Kenya, Nigeria and South Africa.
Witty said, “We are setting out further steps to tackle Africa’s dual health burden of infectious and emerging non-communicable diseases and help build crucial capacity to underpin the development of the healthcare sector in the region. We have a unique opportunity to deliver meaningful social and economic value to all of the communities we work in—using our scientific expertise and our global reach to develop innovative medicines and deliver them to people who need them around the world.”
He continued, “With global attention focused on how we support development beyond 2015, now is the moment for business to play a more active role in contributing to a more prosperous future in Africa, investing in infrastructure, building skills and capability to unlock human potential and create jobs. Our long-term goal is to equip Africa to discover, develop and produce the medicines required for Africa.”
GSK will invest $41.6 million to create the world’s first R&D Open Lab for non-communicable diseases (NCDs) in Africa. This builds on the success of GSK’s Open Lab in Tres Cantos, Spain, which gives independent researchers access to GSK facilities, resources and knowledge to help them advance their own research projects into diseases of the developing world such as malaria, tuberculosis and leishmaniasis.
The new R&D Open Lab for NCDs in Africa will see GSK scientists collaborate with research and scientific centers across Africa from its hub at GSK’s Stevenage R&D facility in the U.K. to conduct high-quality epidemiological, genetic and interventional research to increase understanding of NCDs in Africa. An independent governing board of leading scientists and clinicians will oversee the implementation of NCD research projects within a dynamic and networked open innovation environment.
The open lab aims to improve understanding of NCD variations seen in the Africa setting, which could include for example the apparent higher prevalence of treatment-resistant hypertension and aggressive breast cancers in younger women. It is hoped that these insights will inform prevention and treatment strategies and will enable researchers across academia and industry to discover and develop new medicines to address the specific needs of African patients.
Over the next five years, GSK will look to partner with a number of African countries to develop domestic manufacturing capacity and capability, with GSK investing up to $166.4 million to expand its existing manufacturing capability in Nigeria and Kenya and build up to five new factories in Africa. The company currently is reviewing possible locations in countries including Rwanda, Ghana and Ethiopia and the selected sites will be announced in due course and subject to government agreement.
The new facilities will be built to globally recognized good manufacturing practice (GMP) standards and will make locally relevant products such as antibiotics and respiratory and HIV medicines (on behalf of ViiV Healthcare). The initial focus will be on secondary manufacture with the aim to transfer the technology, skills and knowledge needed to enable the local manufacture of more complex products over time. The factories will create a network of localized industry and local employment for a highly skilled workforce drawn from surrounding communities.
To support the scale-up of domestic manufacturing and supply, GSK will establish up to 25 academic chairs at local African universities in related areas such as pharmaceutical sciences, public health, engineering and logistics. These roles will facilitate the development of new courses as well as internships and student exchanges, and will be pivotal to ensuring manufacturing capability is locked into the continent to help attract further manufacturing investment.
GSK also is taking steps to improve and simplify its supply chain with the creation of regional supply hubs that will help to reduce stock shortages and local supply partnerships to enable more GSK products and medicines to reach under-served rural communities in Africa. These steps will help reduce Africa’s reliance on imported medicines, improving the security of supply and reducing production costs and transportation which in time should help contribute to lower prices.
GSK will optimize its portfolio of medicines for NCDs by working in collaboration with its local partner, Aspen, and with regulators to increase the registration of medicines and vaccines in its existing portfolio, such as its Amoxil antibiotic and its Ventolin respiratory medicine, where not already available.
At the same time, the company continues to work to develop new products designed to meet the specific needs of Africa, for example through its ongoing work with partners to develop the world’s first vaccine against malaria and to create new nutritional products fortified with micro-nutrients to tackle childhood malnourishment.
GSK also will increase its support for community health worker training, in recognition of the vital role they play in delivering basic healthcare to many communities. As part of its initiative to reinvest 20% of any profits generated in LDCs back into strengthening healthcare infrastructure in those countries, GSK already is supporting the training of 15,000 healthcare workers with its NGO partners by the end of 2014.
GSK’s commitment to healthcare worker training now will be expanded to include low- and middle-income countries in sub-Saharan Africa. Over the next three years, GSK will partner with charities to help train and upskill 10,000 community healthcare workers across Kenya, Ghana and Nigeria under the umbrella of the One Million Community Health Worker campaign, a UN-led initiative directed by Professor Jeffrey Sachs. The investment will be targeted at supporting the most remote and marginalized communities to help address healthcare inequalities that exist even in fast-growing countries.
These changes build on steps taken by GSK over the past six years to modernize its business model and help improve access to medicines in developing countries. This has seen the company cap the prices of its patented medicines at no more than 25% of developed world prices and reinvest 20% of any profit made back into training healthcare workers in the world’s poorest countries and pursue open innovation models for diseases of the developing world.